Biomarker - 3.21 Biomarkers in acute cardio-reno-metabolic disease states

"Acute dearrangements in the cardio-reno-metabolic axis encompass complex and potentially acutly life-thretening conditions in a large group of patients in the intensive care unit setting. This project focuses on identifying, validating and translating biomarkers for the monitoring of a patients’ clinical course, specifically targeting treatment response as well as metabolites explaining mechanisms of action of used drugs. Comprehensively, in-silico modelling using computational methods is combined with conventional molecular biomarkers. CBmed project 3.3 proved the feasibility of in-silico modelling in acute kidney injury in critically ill patients by targeting patients’ fluid balance. Additionally, the Medical University of Graz under the leadership of Prof. Von Lewniski and Prof. Sourij designed and set up a multicenter, randomized, placebo-controlled trial investigating the impact of Empaglifozin on cardiac function and biomarkers for heart failure in patients with acute myocardial infarction (EMMY trial). The closely linked fields of cardio and renal biomarkers shall provide the opportunity to combine efforts in clinical decision support regarding improvements in monitoring the clinical course, as well as guiding related treatments. This will strengthen understanding of the cardio-renal axis and provide new opportunities to foster treatment efficacy for affected patients. The integration of in-silico modelling and conventional biomarkers into a digital platform for clinical decision support, takes into account CBmed’s strategy to enable cutting-edge technologies for patient care and adds up to digitalization initiatives targeting intensive care medicine with focus on the cardio-reno-metabolic axis."